Key Takeaway
The GLP-1 drug shortage compounding relationship is one of the most important regulatory topics for patients seeking affordable treatment. When a brand-name drug is listed on the FDA's drug shortage list, it opens the door for compounding pharmacies to prepare that medication more broadly.
The GLP-1 drug shortage compounding relationship is one of the most important regulatory topics for patients seeking affordable treatment. When a brand-name drug is listed on the FDA's drug shortage list, it opens the door for compounding pharmacies to prepare that medication more broadly. When it comes off the list, the rules tighten. Understanding this dynamic helps you stay informed about your treatment options.
Key Takeaways: - Learn how the fda drug shortage list works - Semaglutide Shortage History and Current Status - Tirzepatide: What Happened After October 2024 - Learn how shortage status affects your treatment - Understand what to do if your medication access changes
Here is how shortage status works and what it means for you.
How the FDA Drug Shortage List Works
The FDA maintains a list of drugs that are currently in shortage. A shortage occurs when the total supply of all commercially available versions of a drug cannot meet demand. The FDA tracks shortages to help healthcare providers find alternative sources and to protect patient access to needed medications.
Drug shortages can happen for many reasons. Manufacturing problems, raw material shortages, increased demand, and supply chain disruptions all contribute. When demand for GLP-1 medications exploded in 2023 and 2024, both semaglutide and tirzepatide landed on the shortage list because manufacturers could not produce enough to meet the unprecedented demand.
The shortage list is publicly available on the FDA's website. You can search by drug name to see its current status, the reason for the shortage, and any available alternatives.
Being on the shortage list has specific legal implications for compounding pharmacies. Under federal law, 503A pharmacies can compound medications that are on the shortage list even if a commercially available version exists. This is an important exemption because it expands patient access during periods when the brand-name product is hard to get.
"We now have cardiovascular outcomes data showing semaglutide reduces MACE events by 20% in people with obesity, independent of diabetes status. The SELECT trial changed how we think about these medications.") Dr. A. Michael Lincoff, MD, Cleveland Clinic, lead author of SELECT
When a drug comes off the shortage list, the compounding rules change. 503A pharmacies may need to demonstrate a clinical need for a personalized formulation rather than simply compounding a copy of the commercial product.
Semaglutide Shortage History and Current Status
Semaglutide has had a complex shortage history. The injectable forms were listed on the FDA shortage list for an extended period as demand from both diabetes and weight management patients far exceeded manufacturing capacity.
During the shortage period, compounding pharmacies were able to prepare semaglutide for patients who could not access the brand-name products. This significantly expanded access to affordable GLP-1 treatment for patients who might otherwise have gone without.
The shortage status has evolved over time as the manufacturer increased production capacity and new formulations entered the market. The market continues to shift, and the current status affects what compounding pharmacies can legally prepare.
Free Download: Compounding Pharmacy Verification Checklist Stay informed about your medication source. This checklist helps you verify pharmacy quality regardless of shortage status changes. Get yours free (we'll email it to you instantly.
[Download CTA Button]
For the most current information on semaglutide shortage status, check the FDA's drug shortage database directly. Your provider and pharmacy also track this information and can advise you on how any changes affect your treatment.
If you are currently taking compounded semaglutide, a change in shortage status does not necessarily mean your treatment will be disrupted. The regulatory details depend on the specific circumstances and the compounding pathway your pharmacy uses. Your .
Tirzepatide: What Happened After October 2024
Tirzepatide came off the FDA shortage list in October 2024. This was a significant moment for patients and compounding pharmacies alike because it changed the legal framework for compounding this medication.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →When tirzepatide was on the shortage list, compounding pharmacies could prepare it relatively freely. Once it came off the list, 503A pharmacies could no longer compound it under the shortage exemption alone. They needed to demonstrate a clinical need for a personalized formulation that differed from the commercially available product.
This triggered legal battles. The manufacturer filed lawsuits against compounding pharmacies and telehealth companies that continued to offer compounded tirzepatide. Several court decisions shaped the market, and the situation remained fluid.
For patients, the practical impact varied. Some compounding pharmacies stopped offering tirzepatide. Others continued under different legal theories about personalized compounding. Some patients switched to or brand-name tirzepatide products.
The key takeaway is that shortage status directly affects your access to compounded medications. Working with a provider and pharmacy that stay current on regulatory changes protects you from disruptions.
How Shortage Status Affects Your Treatment
If you are currently on compounded GLP-1 medication, shortage status changes can affect you in several ways.
Availability. If a drug comes off the shortage list, your pharmacy may no longer be able to compound it under the same legal framework. You might need to switch to a different medication, a different formulation, or a brand-name product.
Price. Shortage status affects the market. When compounding is broadly available, prices tend to be lower. When compounding options narrow, remaining providers may adjust pricing. Brand-name products remain at their retail price regardless.
Formulation. Even when shortage-based compounding is restricted, 503A pharmacies may still compound a medication if the formulation is meaningfully different from the commercial product. This could mean a different concentration, a different delivery method, or a combination product that is not commercially available.
Continuity of care. A well-prepared provider and pharmacy anticipate regulatory changes and communicate with patients proactively. If a change is coming, you should hear about it before your medication runs out, not after.
The best protection against disruption is working with a provider who monitors the market and has contingency plans. FormBlends stays current on all to minimize the impact on patient care.
What to Do If Your Medication Access Changes
If you learn that your compounded medication may be affected by a shortage status change, here is what to do.
First, do not panic. Regulatory changes typically come with notice periods. You will not wake up one day unable to refill your medication without warning.
Second, talk to your provider. They can explain the options available to you. This might include switching to a different compounded formulation, transitioning to a brand-name product, trying a different GLP-1 medication, or exploring insurance coverage for brand-name options.
Third, do not stockpile. Compounded medications have limited shelf lives, and hoarding creates its own safety risks. Trust your provider and pharmacy to manage the supply chain.
Fourth, verify any alternative sources carefully. When medication access tightens, questionable suppliers emerge. Do not turn to unverified online sources or overseas pharmacies. The risks far outweigh the cost savings. Use our to evaluate any new source.
Frequently Asked Questions
Does the FDA shortage list update frequently?
The FDA updates its shortage list as conditions change. Some drugs move on and off the list multiple times. You can check the current status at any time on the FDA's drug shortage database. Your provider should also inform you of any changes that affect your treatment.
Can compounding pharmacies still make GLP-1 medications when they are not on the shortage list?
503A pharmacies may compound medications that are not on the shortage list if there is a clinical need for a personalized formulation. This means the compounded product must differ from the commercial product in a meaningful way, such as a different concentration or combination. The specific rules are complex and vary by interpretation.
Will my medication cost more if the shortage ends?
It depends. When compounding options narrow, remaining providers may adjust prices. However, brand-name manufacturers sometimes introduce savings programs or lower-cost formulations to compete. Your provider can help you find the most cost-effective option for your situation.
How do I check if my GLP-1 medication is currently on the shortage list?
Visit the FDA's drug shortage database at accessdata.fda.gov and search for semaglutide or tirzepatide. The listing shows current shortage status, the manufacturer, and any available alternatives. You can also ask your provider or pharmacy for the most current information.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide (no pressure, no commitment.
Sources & References
- Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections) United States, 2012. MMWR. 2012;61(41):839-842.
- U.S. Food and Drug Administration. Drug Quality and Security Act (DQSA). Public Law 113-54. November 27, 2013.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
The information in this article is intended for educational use only and should not be considered medical advice. Consult a qualified healthcare provider before making any changes to your medication or supplement regimen. FormBlends helps with connections with licensed providers for personalized medical guidance.
Last updated: 2026-03-24